Last $62.23 USD
Change Today +1.80 / 2.98%
Volume 428.3K
CRL On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 8:04 PM 10/21/14 All times are local (Market data is delayed by at least 15 minutes).

charles river laboratories (CRL) Snapshot

Open
$60.71
Previous Close
$60.43
Day High
$62.35
Day Low
$60.71
52 Week High
03/18/14 - $62.50
52 Week Low
10/23/13 - $47.33
Market Cap
2.9B
Average Volume 10 Days
604.8K
EPS TTM
$2.62
Shares Outstanding
46.7M
EX-Date
--
P/E TM
23.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for CHARLES RIVER LABORATORIES (CRL)

charles river laboratories (CRL) Related Bloomberg News

View More Bloomberg News

charles river laboratories (CRL) Related Businessweek News

No Related Businessweek News Found

charles river laboratories (CRL) Details

Charles River Laboratories International, Inc., together with its subsidiaries, provides research models and associated services, and outsourced preclinical services to accelerate the drug discovery and development process. It operates through two segments, Research Models and Services (RMS), and Preclinical Services (PCS). The RMS segment produces and sells research model strains, principally genetically and microbiologically defined purpose-bred rats and mice for use by researchers. This segment also offers a range of services to assist customers in the drug discovery and development process, which include genetically engineered models and services, insourcing solutions, discovery research services, and research animal diagnostic services; endotoxin and microbial detection products and services; and avian vaccine products and services. The PCS segment provides preclinical services, including in vivo and in vitro studies, supporting laboratory services, and strategic preclinical consulting and program management to support product development. This segment offers services in the areas of bioanalysis, pharmacokinetics, and drug metabolism; toxicology; and pathology services, as well as testing of biologics and devices frequently outsourced by pharmaceutical and biotechnology companies. The company serves pharmaceutical companies, biotechnology companies, government agencies, hospitals, and academic institutions worldwide. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

7,700 Employees
Last Reported Date: 02/25/14
Founded in 1947

charles river laboratories (CRL) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $1.1M
Chief Financial Officer and Corporate Executi...
Total Annual Compensation: $512.2K
Corporate Executive Vice President and Presid...
Total Annual Compensation: $450.9K
Chief Scientific officer and Corporate Execut...
Total Annual Compensation: $500.5K
Corporate Executive Vice President of Global ...
Total Annual Compensation: $400.5K
Compensation as of Fiscal Year 2013.

charles river laboratories (CRL) Key Developments

Charles River Mulls Acquisitions

Charles River Laboratories International, Inc. (NYSE:CRL) intends to pursue acquisitions."We want to be able to participate in that market, which is growing disproportionately fast from a funding point of view, to the rest of the world. And we think we have a lot to offer. But we're going to do that cautiously and we're continuing to assemble a strong management team in China and as we do that. So we're looking at several acquisition opportunities and several organic growth opportunities," Jim Foster, Chairman, President and Chief Executive Officer of Charles River, said.

Charles River Laboratories International, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 28, 2014; Provides Earnings Guidance for the Third Quarter and Revises Earnings Guidance for the Full Year 2014

Charles River Laboratories International, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 28, 2014. For the quarter, the company's revenue was $341.179 million compared with $292.933 million a year ago. Operating income was $51.025 million compared with $43.188 million a year ago. Income from continuing operations before income taxes was $50.541 million compared with $36.847 million a year ago. Income from continuing operations, net of tax was $36.460 million or $0.75 per diluted share compared with $28.628 million or $0.58 per basic and diluted share a year ago. Net income attributable to common stockholders was $35.264 million or $0.74 per diluted share compared with $27.284 million or $0.56 per diluted share a year ago. Capital expenditures were $9.315 million compared with $9.795 million a year ago. Non-GAAP operating income was $64.799 million compared with $50.878 million a year ago. Non-GAAP net income from continuing operations was $46.256 million or $0.97 per diluted share compared with $35.668 million or $0.73 per diluted share a year ago. For the six months, the company's revenue was $640.547 million compared with $584.171 million a year ago. Operating income was $90.731 million compared with $85.951 million a year ago. Income from continuing operations before income taxes was $93.527 million compared with $72.495 million a year ago. Income from continuing operations, net of tax was $69.088 million or $1.43 per diluted share compared with $54.554 million or $1.11 per diluted share a year ago. Net income attributable to common stockholders was $67.496 million or $1.41 per diluted share compared with $52.862 million or $1.09 per diluted share a year ago. Capital expenditures were $20.505 million compared with 16.223 million a year ago. Non-GAAP operating income was $115.779 million compared with $99.831 million a year ago. Non-GAAP net income from continuing operations was $85.530 million or $1.79 per diluted share compared with $68.894 million or $1.42 per diluted share a year ago. Net cash provided by operating activities was $85.438 million compared with $78.943 million a year ago. The company is raising its 2014 net revenue guidance to 9%-11% compared with previous guidance of 9%-11%. Non-GAAP earnings per share increase to a range of $3.25 to $3.35 compared to previous guidance of $3.15 - $3.25. The company estimates GAAP EPS in the range of $2.60 - $2.70 compared to previous guidance of $2.64 - $2.74. The company also estimates amortization of intangible assets of $0.36 compared to previous guidance of $0.33 and operating losses of $0.06 compared to previous guidance of $0.04. Guidance for non-GAAP earnings per share has been increased to primarily reflect the strong second-quarter performance, including the gain from limited partnership investments. Primarily as a result of additional charges associated with the company's global efficiency initiatives, GAAP earnings per share guidance has been reduced. The company is maintaining its 2014 revenue guidance and continues to expect foreign currency translation to provide only a small benefit to reported revenue. Free cash flow in a range of $180 million to $190 million in 2014, and capex of $55 million to $65 million. Non-GAAP tax rate for 2014 to be in a range of 27% to 28%. 2014 consolidated non-GAAP operating margin, the company expects to be similar or slightly higher than 2013 where it was 17.3%. For the third quarter of 2014, the company expects revenue to be in the low double digits year-over-year basis, including Argenta and BioFocus. The company expects non-GAAP EPS to be similar to third quarter of 2013 where it was $0.79. The company would actually be up over 10% to non-GAAP EPS in the third quarter looking at last year.

Charles River Laboratories International, Inc. - Shareholder/Analyst Call

To present an overview of company's business and strategic focus

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CRL:US $62.23 USD +1.80

CRL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Covance Inc $80.41 USD +2.68
Ergomed PLC 139.50 GBp 0.00
ICON PLC $56.91 USD +0.97
PAREXEL International Corp $63.63 USD +2.89
WuXi PharmaTech Cayman Inc $36.43 USD +1.73
View Industry Companies
 

Industry Analysis

CRL

Industry Average

Valuation CRL Industry Range
Price/Earnings 24.5x
Price/Sales 2.3x
Price/Book 4.2x
Price/Cash Flow 20.5x
TEV/Sales 1.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHARLES RIVER LABORATORIES, please visit www.criver.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.